CA-19-9: Difference between revisions
No edit summary |
|||
| Line 51: | Line 51: | ||
==Related chapters== | ==Related chapters== | ||
*[[ | *[[CA 19-9]] | ||
==References == | ==References == | ||
Revision as of 20:56, 21 January 2012
| CA-19-9 |
|
WikiDoc Resources for CA-19-9 |
|
Articles |
|---|
|
Most recent articles on CA-19-9 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CA-19-9 at Clinical Trials.gov Clinical Trials on CA-19-9 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CA-19-9
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating CA-19-9 Risk calculators and risk factors for CA-19-9
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CA-19-9 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
CA-19-9 is a tumor marker.
Interpretation
CA 19-9 is elevated in most patients with advanced pancreatic cancer, but it may also be elevated in other cancers, conditions, and diseases such as colorectal cancer, lung cancer, gallbladder cancer, gallstones, pancreatitis, cystic fibrosis, and liver disease.
Other causes of bile duct obstruction may also cause very high CA 19-9 levels, which fall when the blockage is cleared.
If the bile ducts are blocked, wait a week or two after the blockage is removed or treated to check CA 19-9 levels.
Differential Diagnosis
In alphabetical order. [1] [2]
Increased level of CA-19-9
Malignant Diseases
- Biliary tract carcinoma
- Breast Cancer
- Bronchial carcinoma
- Colorectal Cancer
- Gastric carcinoma
- Liver carcinoma
- Ovarian Cancer
- Pancreatic Cancer
- Uterine Cancer